Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479995 | 1.00 | FOLH1 (0.47) | FOLH1NAALAD2RIMKLAGLO1PTGS1 | |
| SCHEMBL31479983 | 0.95 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGLO1PTGS1 | |
| SCHEMBL8361988 | 0.93 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAGLO1GNPAT | |
| SCHEMBL8361982 | 0.93 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAGLO1GNPAT | |
| SCHEMBL30099483 | 0.92 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGLO1GNPAT | |
| SCHEMBL30099577 | 0.92 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGLO1GNPAT | |
| SCHEMBL30261857 | 0.91 | FOLH1 (0.47) | FOLH1NAALAD2RIMKLAGLO1GNPAT | |
| SCHEMBL30099613 | 0.91 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGNPATSLC15A2 | |
| SCHEMBL30565198 | 0.91 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGNPATSLC15A2 | |
| SCHEMBL32670748 | 0.90 | GLO1 (0.49) | FOLH1NAALAD2RIMKLAGLO1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | FOLH1 120/4885NAALAD2 219/4885RIMKLA 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.